Compare MLP & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLP | OABI |
|---|---|---|
| Founded | 1909 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.8M | 277.8M |
| IPO Year | 1972 | N/A |
| Metric | MLP | OABI |
|---|---|---|
| Price | $16.89 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 18.8K | ★ 481.6K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $18,344,000.00 | ★ $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.55 | 3.36 |
| 52 Week Low | $13.84 | $1.22 |
| 52 Week High | $21.34 | $4.02 |
| Indicator | MLP | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 50.49 |
| Support Level | $16.75 | $1.86 |
| Resistance Level | $17.34 | $1.95 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 29.13 | 60.00 |
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.